Chronic immune activation and elevated numbers of circulating activated monocytes (CD16+) are implicated in HIV-associated neuroinflammation. The objective was to compare the level of circulating CD16+ monocytes and IFN-γ-inducible protein 10 (IP-10) between HIV-infected cannabis users (HIV+MJ+) and noncannabis users (HIV+MJ−) and determine whether in-vitro 9-Tetrahydrocannabinol">Δ9-Tetrahydrocannabinol (THC), a constituent of cannabis, affected CD16 expression as well as IP-10 production by monocytes.
The levels of circulating CD16+ monocytes and IP-10 from HIV+MJ− and HIV+MJ+ donors were examined. In-vitro experimentation using THC was performed on primary leukocytes isolated from HIV−MJ−, HIV+MJ− and HIV+MJ+ donors to determine if THC has an impact on CD16+ monocyte and IP-10 levels.
Flow cytometry was used to measure the number of blood CD16+ monocytes and plasma IP-10 from HIV+MJ− and HIV+MJ+ donors. Peripheral blood mononuclear cells were isolated from HIV−MJ− and HIV+ (MJ− and MJ+) donors for in-vitro THC and IFNα treatment, and CD16+ monocytes and supernatant IP-10 were quantified.
HIV+MJ+ donors possessed a lower level of circulating CD16+ monocytes and plasma IP-10, compared with HIV+MJ− donors. Further, monocytes from HIV+MJ+ donors were unable to induce CD16 expression when treated with in-vitro IFNα, whereas HIV−MJ− and HIV+MJ− donors displayed pronounced CD16 induction, suggesting anti-inflammatory effects by cannabis. Lastly, in-vitro THC treatment impaired CD16− monocyte transition to CD16+ and monocyte-derived IP-10.
Components of cannabis, including THC, may decelerate peripheral monocyte processes that are implicated in HIV-associated neuroinflammation.
Supplemental Digital Content is available in the text
aCell & Molecular Biology Program
bInstitute for Integrative Toxicology
cDepartment of Pharmacology & Toxicology
dDepartment of Microbiology & Molecular Genetics
eDepartment of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, USA.
Correspondence to Norbert E. Kaminski, Department of Pharmacology & Toxicology, Michigan State University, East Lansing, Michigan, USA. Tel: +1 517 353 3786; e-mail: firstname.lastname@example.org
Received 28 August, 2017
Revised 20 October, 2017
Accepted 31 October, 2017
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).